pmvpharmalogo.jpg
PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53
November 23, 2020 08:00 ET | PMV Pharmaceuticals, Inc.
PC14586 targets p53 Y220C mutants to selectively reactivate p53, restoring the protein’s tumor-suppressing functionPhase 1/2 study is enrolling patients with advanced solid tumors that have a p53...
Logo_final_color.png
Cybrexa Therapeutics to Present First Efficacy and Safety Data From Its Lead Program CBX-12 and Initial Data From CBX-13 at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
May 15, 2020 04:00 ET | Cybrexa Therapeutics
NEW HAVEN, Conn., May 15, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Autolus Therapeutics and Noile-Immune Announce Licensing Agreement
November 13, 2019 06:30 ET | Autolus Therapeutics plc
LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Noile-Immune...
Autolus Announces Data Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 03, 2019 09:08 ET | Autolus Therapeutics plc
LONDON, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Thymidine Kinase 1 can be used for early detection of therapy response in breast cancer treatment
September 18, 2019 11:10 ET | AroCell AB
Patients treated with Epirubicin and Docetaxel before surgery were followed by their thymidine kinase (TK1) levels in blood to directly observe treatment response. The results show that a TK1-based...
Tymidinkinas 1 kan användas för tidigt terapisvar vid behandling av bröstcancer
September 18, 2019 11:10 ET | AroCell AB
Patienter behandlade med Epirubicin och Docetaxel före operationen följdes med deras tymidinkinas (TK1) nivåer i blodet för att direkt observera behandlingssvaret. Resultaten visar att en TK1-baserat...
AroCell AB (publ) Interim Report January 1st to June 30th 2019
August 21, 2019 02:00 ET | AroCell AB
Word from the CEO “It is with pleasure that I can say that the second quarter of 2019 became one of the most exciting and active quarters in AroCell's history. The goal of establishing AroCell as...
AroCell AB (publ) Delårsrapport 1 januari – 30 juni 2019
August 21, 2019 02:00 ET | AroCell AB
VD-ORD ”Det är med glädje som jag kan konstatera att det andra kvartalet 2019 blev ett av det mest spännande och aktiva kvartal i AroCells historia. Målet att etablera AroCell som den givne partnern...
LogoTransparentbg.png
DrugCendR Inc. Announces the Appointment of Dr. Daniel Von Hoff as Clinical Advisor
August 20, 2019 13:17 ET | DrugCendR Inc.
LA JOLLA, Calif., Aug. 20, 2019 (GLOBE NEWSWIRE) -- DrugCendR, Inc., a clinical-stage biotech company developing next generation therapies for the treatment of solid tumors, today announced that Dr....
AroCell signs a new distributor agreement in the USA and Canada
August 06, 2019 02:15 ET | AroCell AB
AroCell AB (publ) announced today that it has signed a distribution agreement with Diapharma Group of West Chester Ohio for the promotion and distribution of the AroCell TK 210™ ELISA in the United...